Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Close
Search
Search
In Vivo
Generics Bulletin
HBW Insight
Medtech Insight
Pink Sheet
Scrip
Nine More Years? Sandoz Loses Again On Enbrel Biosimilar
Sandoz Has Held FDA Approval For Its Erelzi Version Since 2016
Jul 02 2020
•
By
Dean Rudge
Sandoz' biosimilar etanercept launch plans may be on ice until 2029 • Source: Shutterstock
More from Legal & IP
More from Generics Bulletin